Workflow
助力细胞治疗产业化,济南推出首台国产双智能化细胞制备平台
Qi Lu Wan Bao Wang·2025-08-01 07:20

Core Viewpoint - The launch of the dual intelligent cell production and storage management platform marks a significant advancement in China's cell and gene therapy (CGT) industry, which is expected to grow substantially by 2030, reaching a global market size of $11 billion [1][2]. Group 1: Industry Insights - The CGT industry is recognized as a key area of support by the Chinese government, as outlined in the "Healthy China 2030" initiative, positioning cell therapy as an important sector for new productive forces [1]. - The global cell manufacturing market is projected to reach $11 billion by 2030, indicating a growing demand for advanced cell manufacturing technologies [1]. - China's CGT industry is still in its early stages, with the cell preparation market largely dominated by foreign companies, facing challenges such as high costs and low flexibility [1]. Group 2: Company Developments - The dual intelligent cell production and storage management platform is the first fully automated system in China that caters to both adherent and suspension cell cultures, showcasing significant technological innovation [2][3]. - The platform integrates expertise from various institutions, including the Shenzhen Institute of Advanced Technology, Nanyang Technological University, and Shandong University, demonstrating a successful collaboration between academia and industry [3]. - The platform achieves two major technological breakthroughs: redefining cell manufacturing standards through automation and machine learning, and revolutionizing sample management in ultra-low temperature environments [3].